Inventor
MARK E. LAYTON
Inventor
US
Overview
Patents· 7 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations35%
C07DHeterocyclic compounds35%
A61KPreparations for medical, dental or toiletry purposes30%
PatentTitleYear
12,516,0462-oxo-oxazolidine-5-carboxamides as NAV1.8 inhibitors202612,427,159Hydroxypyrrolidine-substituted arylsulfonamide compounds with selective activity in voltage-gated sodium channels202512,344,5952-amino-n-phenyl-nicotinamides as NAV1.8 inhibitors202512,246,0084-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels202512,195,4452-amino-N-heteroaryl-nicotinamides as Na202511,802,1222-oxoimidazolidine-4-carboxamides as NA202311,377,4382-amino-n-heteroaryl-nicotinamides as Na2022Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2022–2026Patents assigned to MERCK SHARP & DOHME LLC (7)· patent assignee history
2022–2023Patents assigned to MERCK SHARP & DOHME (2)· patent assignee history
2022–2026Based in US· patent location history
2025Patents assigned to LAYTON MARK E (1)· patent assignee history
2025Patents assigned to PENG XUANJIA (1)· patent assignee history
2025Patents assigned to ROECKER ANTHONY J (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| MERCK SHARP & DOHME LLC | 7 | 2022–2026 |
| MERCK SHARP & DOHME | 2 | 2022–2023 |
| LAYTON MARK Eself | 1 | 2025 |
| PENG XUANJIA | 1 | 2025 |
| ROECKER ANTHONY J | 1 | 2025 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 7 | 2022–2026 |